

December 21, 2022 | Issue 252

Editor's note

Due to the holidays, we are providing an early issue of ATW 360 this week and will not publish next Friday, December 30th. We'll be back with our next issue on January 7th. The KPMG Center for Healthcare Regulatory Insight team wishes you the best of the holiday season and a great New Year!

This note is produced every Friday by the <u>KPMG Center for Healthcare Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.





Healthcare regulatory news

CMS proposed standards for electronic health care attachments transactions.

HHS <u>released ownership information</u> for all 7,000+ Medicare-certified hospitals... HHS will award \$130B+ in 988 Suicide & Crisis Lifeline grants.

NIH <u>launched a research network</u> to test efficacy of harm-reduction services/tools.

FDA <u>approved the first gene therapy</u> for high-risk, non-muscle-invasive bladder cancer... FDA <u>declared</u> a <u>shortage of Lilly's diabetes drug</u> Mounjaro... FDA <u>lifted a partial clinical hold</u> on studies of Bluebird bio's sickle cell disease therapy... FDA <u>revised guidance</u> on <u>applicant timeframes for responding to complete response letters</u> to abbreviated new drug applications.

An <u>FDA-commissioned report</u> found the agency's Center for Tobacco Products <u>has not</u> effectively regulated the industry, particularly vaping products.

A DEA investigation <u>found Truepill filled illegitimate prescriptions</u> (from unlicensed providers or surpassing 90-day supply limits) for ADHD treatments.

OIG reported <u>Medicare Part B spending on lab tests increased 17% last year to \$9.3B</u>, driven by COVID-19 tests and demand for genetic tests... OIG <u>recommended</u> CMS issue instructions/guidance to administrative contractors to <u>improve review of Medicare bad debt</u> reimbursement claims.



Healthcare law and policy news

Congress is expected to pass and President Biden to sign an omnibus FY2023 appropriations bill on funding. The package includes several healthcare policy provisions including: reducing Medicare physician payment cuts to 2% in 2023 and 3.5% in 2024; allowing states to begin Medicaid eligibility redeterminations in April, regardless of when the PHE ends; extending pandemic telehealth policies by two years; extending hospital at-home waivers for two years; reforms to the FDA Accelerated Approval pathway; and, extending Advanced APM bonus payments for an additional year at 3.5%.

Cooper University Health Care and Cape Regional Health System <u>plan to merge</u>, creating a \$2.2B system... Kite <u>will acquire Tmunity Therapeutics</u>... Signify Health and Ardent Health Services <u>expanded their accountable care</u> partnership.

Wall Street Journal reported on (1) <u>shortcomings of online mental health</u> company offerings and (2) 340B Program spending accountability.

The Joint Commission will <u>make major revisions</u> to its quality and safety standards, including retiring 14% of its quality standards, effective January 1 and <u>announced a Health Care Equity certification</u> program.

KFF reported ACA <u>benchmark silver plan premiums are increasing</u> on average by 4.1% in 2023.

Special Section: COVID-19, Respiratory Illnesses, and Monkeypox News

FDA's Vaccines and Related Biological Products Advisory Committee will meet January 26th to consider whether to update the primary series of COVID-19 vaccines to a bivalent version.

USAging and the National Council on Aging will receive a combined \$125M from HHS to bolster efforts to vaccinate the most at-risk older Americans and people with disabilities for COVID-19 and the flu.

The Supreme Court temporarily halted the end of the Title 42 immigration policy, pending the court's decision on whether to hear a Republican-led states' challenge to keep the policy in place.

ICER cut its suggested price range for Pfizer's Paxlovid by more than 80% to reflect common thresholds of cost-effectiveness.

> Questions or comments, please send to us-hcinsight@kpmg.com.



kpmg.com/socialmedia











Privacy | Legal

This email was sent by KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2022 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP295619-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.